{rfName}
Th

Indexed in

License and use

Icono OpenAccess

Citations

8

Altmetrics

Analysis of institutional authors

Portolés JmAuthorOrtega-Carrion AAuthor

Share

April 21, 2021
Publications
>
Article
Sí

The Immunobiogram, a Novel In Vitro Assay to Evaluate Treatment Resistance in Patients Receiving Immunosuppressive Therapy

Publicated to:Frontiers in Immunology. 11 (618202): 618202-618202 - 2021-01-25 11(618202), DOI: 10.3389/fimmu.2020.618202

Authors: Portoles JM, Jimenez C, Janeiro D, Lopez-Oliva MO, Ortega-Carrion A, Blanquez D, Arribas L, Gomez C, Diez T, Pascual J, Portero I

Affiliations

Adamas Engineering Consulting, Madrid, Spain. - Author
Adamas Engn Consulting, Madrid, Spain - Author
BIOHOPE Sci SL, Dept R D, Madrid, Spain - Author
Department of Nephrology, Hospital del Mar, Institut Mar for Medical Research, Barcelona, Spain. - Author
Department of Nephrology, Hospital La Paz, Madrid, Spain. - Author
Department of Nephrology, Hospital Universitario Puerta de Hierro, Madrid, Spain. - Author
Hosp La Paz, Dept Nephrol, Madrid, Spain - Author
Hosp Mar, Inst Mar Med Res, Dept Nephrol, Barcelona, Spain - Author
Hosp Univ Puerta Hierro, Dept Nephrol, Madrid, Spain - Author
Inst Salud Carlos III, Res Net REDInREN 016 0009, Madrid, Spain - Author
R+D Department, BIOHOPE Scientific SL, Madrid, Spain. - Author
Research net REDInREN 016/0009, Instituto Salud Carlos III, Madrid, Spain. - Author
See more

Abstract

Immunosuppressive drugs are widely used to treat several autoimmune disorders and prevent rejection after organ transplantation. However, intra-individual variations in the pharmacological response to immunosuppressive therapy critically influence its efficacy, often resulting in poor treatment responses and serious side effects. Effective diagnostic tools that help clinicians to tailor immunosuppressive therapy to the needs and immunological profile of the individual patient thus constitute a major unmet clinical need. In vitro assays that measure immune cell responses to immunosuppressive drugs constitute a promising approach to individualized immunosuppressive therapy. Here, we present the Immunobiogram, a functional pharmacodynamic immune cell-based assay for simultaneous quantitative measurement of a patient's immune response to a battery of immunosuppressive drugs. Peripheral blood mononuclear cells collected from patients are immunologically stimulated to induce activation and proliferation and embedded in a hydrogel mixture in which they are exposed to a concentration gradient of the immunosuppressants of interest. Analysis of samples from kidney transplant patients using this procedure revealed an association between the sensitivity of individual patients to the immunosuppressive regimen and their immunological risk of transplant rejection. Incorporation of the Immunobiogram assay into clinical settings could greatly facilitate personalized optimization and monitoring of immunosuppressive therapy, and study of the mechanisms underlying resistance to immunosuppressants.Copyright © 2021 Portoles, Jimenez, Janeiro, Lopez-Oliva, Ortega-Carrion, Blanquez, Arribas, Gomez, Diez, Pascual and Portero.

Keywords

Cellular pharmacodynamicsImmune cell assayImmunosuppressive therapy monitoringPersonalized medicineTransplant rejection

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal Frontiers in Immunology due to its progression and the good impact it has achieved in recent years, according to the agency WoS (JCR), it has become a reference in its field. In the year of publication of the work, 2021, it was in position 35/162, thus managing to position itself as a Q1 (Primer Cuartil), in the category Immunology.

From a relative perspective, and based on the normalized impact indicator calculated from the Field Citation Ratio (FCR) of the Dimensions source, it yields a value of: 1.58, which indicates that, compared to works in the same discipline and in the same year of publication, it ranks as a work cited above average. (source consulted: Dimensions Jul 2025)

Specifically, and according to different indexing agencies, this work has accumulated citations as of 2025-07-18, the following number of citations:

  • WoS: 2
  • Scopus: 3
  • Europe PMC: 1

Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2025-07-18:

  • The use, from an academic perspective evidenced by the Altmetric agency indicator referring to aggregations made by the personal bibliographic manager Mendeley, gives us a total of: 20.
  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 22 (PlumX).

With a more dissemination-oriented intent and targeting more general audiences, we can observe other more global scores such as:

  • The Total Score from Altmetric: 8.45.
  • The number of mentions on the social network X (formerly Twitter): 9 (Altmetric).
  • The number of mentions on Wikipedia: 3 (Altmetric).

It is essential to present evidence supporting full alignment with institutional principles and guidelines on Open Science and the Conservation and Dissemination of Intellectual Heritage. A clear example of this is:

  • The work has been submitted to a journal whose editorial policy allows open Open Access publication.

Leadership analysis of institutional authors

There is a significant leadership presence as some of the institution’s authors appear as the first or last signer, detailed as follows: First Author (PORTOLES PEREZ, JOSE MARIA) .